Blood substitutes: oxygen carriers and plasma expanders

Major categories and characteristics

Broadly, blood substitutes fall into two groups: oxygen-carrying agents and plasma expanders. Oxygen carriers aim to transport oxygen to tissues; plasma expanders restore circulating volume. Important subtypes include:

• Hemoglobin-based oxygen carriers (HBOCs) — chemically modified or encapsulated hemoglobin intended to carry oxygen without intact red cells.
• Perfluorocarbon emulsions (PFCs) — synthetic compounds that dissolve and release oxygen under pressure.
• Plasma expanders — crystalloids and colloids that increase blood volume but do not transport oxygen, such as saline, albumin, and synthetic starches.

Each class has different biochemical properties, shelf life, and storage needs. For technical details and biochemical comparisons see comparative summaries.

History and development

Interest in blood substitutes dates back to wartime and early transfusion research, accelerating when shortages or infection risks made alternatives desirable. Research expanded in the late 20th century with advances in protein chemistry and materials science. Clinical trials have shown promise in some settings but also revealed safety concerns that slowed widespread adoption; regulatory review and further studies continue. A concise timeline and milestones can be found at development history.

Clinical uses and examples

Practical uses include emergency or battlefield care, remote or resource-limited settings, and situations where cross-matched blood is unavailable. Plasma expanders are commonly used in acute resuscitation to maintain perfusion while definitive treatment proceeds. Oxygen therapeutics have been tested to bridge patients until transfusion or surgery. Medical guidance and case examples are summarized at clinical applications and case studies.

Limitations, risks and future directions

Blood substitutes cannot replicate immune functions, platelets, or many plasma proteins needed for clotting. Reported risks include adverse cardiovascular effects, kidney stress, and immune reactions depending on the product. Ongoing research focuses on safer hemoglobin modifications, encapsulation techniques, targeted oxygen delivery, and combined approaches that preserve clotting factors. For regulatory status and ongoing trials see current research and regulatory updates.

Notable distinction: These products are supplements or bridges, not replacements for all functions of whole blood. For further reading and resources consult additional resources.